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Summary
This study aimed to assess the cardio-renal effects of rhEPO therapy on an animal
model of moderate chronic renal failure (CRF). Four groups (n =7) of male rat were
evaluated during a 12-week follow up period: control; rhEPO: 50 IU/Kg/wk; CRF:
two-stage 3/, nephrectomy; CRF+ rhEPO (start after the 3'd wk of surgery). Renal
function, haematology and serum inflammation and redox status were assessed. rhE-
PO treatment was able to partially attenuate renal function markers, totally correct
anaemia, also showing a proliferative and antioxidant action, due to increased serum
TGF-13I and decreased 3-NT. In conclusion, rhEPO therapy might be recommended in
moderate CRF stages in order to efficiently correct not only the underlying anaemia
but also the deleterious cardio-renal effects, due to a proliferative and antioxidant
renoprotective action.
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Introduction
Chronic renal failure (CRF) patients develop anaemia which further promotes
cardiovascular insufficiency. This triad of dysfunctions, already known as cardio-renal
anaemia syndrome, seems to be favoured by the low production of erythropoietin
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therapy has marked a significant advance in the management of anaemia associated
with CRF. However, an increasingly growing body of evidence indicates that thera-
peutic benefits of rhEPO could be far beyond correction of anaemia, namely at the
cardiovascular level (2,3).
The aim of this work was accessed the cardio-renal effects of rhEPO therapy in
moderate CRF stages, using a rat model of % nephrectomy.
Material and Methods
Animal protocol
Four groups (n=7) of male Wistar rats were evaluated during a 12 week follow-up
period: control (without treatment); rhEPO (50 IU/Kg/wk beta Recormon®); CRF and
CRF+rhEPO treated with rhEPO after the 3rd week of surgery. At the final time (15
weeks), blood was collected and kidneys were removed, in order to evaluate renal
function and renal trophism, haematological data, and serum proliferative, inflamma-
tory and redox status markers.
Assays
Renal function: Serum creatinine, ureia and uric acid levels were assessed through
automatic methods/equipments (Hitachi 717 analyser).
Haematological data: Red blood cell (RBC) count, haematocrit (Hct), haemoglobin
(Hb) concentration and reticulocyte (RET) count, were assessed in whole blood EDTA
by using an automatic Coulter Counter® (Beckman Coulter Inc., USA).
Inflammatory and redox status markers: Serum levels of interleukin 2 (IL-2), IL-
143, transforming growth factor (31 (TGF-131) and tumour necrosis factor a (TNF-a)
were measured by ultrasensitive Quantikine® ELISA kits (R&D Systems, Minneapo-
lis, USA). Serum C-reactive protein (CRP) was determined by using an ELISA kit
from Helica Biosystems, Inc. (Fullerton, CA, USA). The thiobarbituric acid reactive-
species (TBARs) assay was used to assess serum products of lipid peroxidation (via
malondialdehyde: MDA) and ferric reducing antioxidant potential (FRAP) assay was
used to estimate total antioxidant status (TAS), as previously described (4). Serum
3-nitrotyrosine (3-NT) was measured by immunoassay (HyCult biotechnology b.v.,
Uden, Netherlands).
Data Analysis
Results are means ± s.e.m. Data was compared using one-way ANOVA and Fisher's
test. Significance was accepted at p less than 0.05.
Results
Renal function
There was a statistically significant increase in serum creatinine and urea 3 weeks
after surgery (data not shown), remaining high along the following 12 weeks. In the
CRF+rhEPO group no significant effects were found (Table 1). The same group still
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Table 1 - Effects of rhEPO treatment in renal function, hemabilogical data, and inflammatory profile and
redox status markers in a rat model of moderate CRF
Parameters






Creatinine (pmol/L) 39.78± 1.77 38.90 ± 2.64 80.44	 5.30 aa 64.53 ± 2.65
Urea (mmol/L) 13.93 ± 0.56 13.78 ± 0.61 24.21 + 1.01 a 22.49 ± 0.99
Uric acid (pmol/L) 36.88 ± 9.52 49.37 ± 8.33 28.55 ± 5.35 36.88 ± 5.95
Haematological data
Hb (g/L) 139.44 ± 3.61 128.72 ± 5.29 13439 ± 2.01 148.81 ± 17.20
Haematocr iti pv 010 ) 0.409 + 0.007 0.361	 0.017 0.395 ± 0.006 0.439 ± 0.056
RBC (x 101'/L) 7.44 + 0.10 6.84 ± 0.38 6.91 ± 0.14 7.83 ± 0.94
RET (x109/L) 383.98 ± 28.97 286.04 * 22.01 326.09	 27.02 228.08 ± 17.98
Kidney trophism
KW/BW (g/kg) 2.62 + 0.05 2.63 ± 0.08 3.96 ± 0.39 5.12 ± 1.49
Inflammatory profile
CRP (itg/m1) 24.78 ± 1.25 24.47 + 0.90 25.83 ± 0.66 26.93 ± 0.98
IL-1p (pg/ml) 26.52 ± 0.94 26.19 ± 0.99 23.76 ± 0.99 27.50 ± 0.95
IL-2 (pg/ml) 36.28 ± 8.70 47.35 t 3.50 49.34 ± 3.43 47.19± 3.50
TNF-a (pg/ml) 16.34± 1.81 17.56 + 2.12 15.75± 1.96 19.85 ± 2.44
Redox status
MDA (prno1/1) 0.27 ± 0.05 0.40 + 0.05 0.34 ± 0.06 0.46 ± 0.10
TM (pmo1/1) 394.72 ± 51.42 475.89 + 122.14 408.03 ± 23.62 431.19 ± 41.82
MDA/TAS 0.56 ± 0.05 0.99 + 0.17 0.73 + 0.21 0.94	 0.18
N: nephrectomy. a -p< 0.05, as -p< 0.01 and aaa -p< 0.001 vs the control group.
showed a trend to increased values of KW/BW when compared with CRF group
(Table I).
Haematological data
Three weeks after nephrectomy, the CRF animals showed a significant decrease
of RBC, Hct and Hb (data not shown), normalizing after 9 weeks after surgery and
remaining stables until the end. The CRF+rhEPO group showed a trend to increased
RBC, HTC and Hb (Table I).
Inflammatory and redox status markers
No significant differences for serum CRP, IL-1 p, IL-2 and TNF-a levels were
observed, but an increment of TGF-fil was found in the CRF rats vs the control.
The CRF+rhEPO group produced no changes for serum CRP, IL-1 p, IL-2 and TNF-a
concentration (Table 1), but imposed a further increase in TGF-fil vs the CRF ani-
mals (Fig. 1A).
No statistically significant changes were found between CRF and control group for
serum MDA and TAS, but a significantly higher 3-NT was found. In the CRF+rhEPO
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Figure 1- Serum levels of transforming growth factor 01 (TGF-01) and 3-nitrotyrosine (3-ND for the groups
under study.
rats there was a trend to increased serum MDA and TAS values (Table 1). However, a
statistically significant reduction of serum 3-NT levels was found between the group
of CRF with rhEPO and those without rhEPO therapy (Fig. 1B).
Conclusions
Our data are consistent with a sustained moderate degree of CRF with development
of moderate and corrected anaemia. The remnant kidney showed a proliferative profile,
with increased mass (hypertrophism), increased levels of serum TGF-(31 and oxidative
stress. rhEPO treatment was able to partially attenuate renal function markers, totally
correct anaemia, also showing a proliferative and antioxidant action.
Thus, rhEPO therapy might be recommended in moderate CRF stages in order to
efficiently correct not only the underlying anaemia but also the deleterious cardio-
renal effects, due to a renoprotective action on the remnant kidney.
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